Principal Financial Group
TBPH icon

Principal Financial Group’s Theravance Biopharma TBPH Stock Holding History

Principal Financial Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Buy
56,792
+4,528
+9% +$75K ﹤0.01% 1944
2026
Q1 		$848K Buy
+52,264
New +$925K ﹤0.01% 1974
2024
Q2 		– Sell
-14,708
Closed -$132K – 2459
2024
Q1 		$132K Sell
14,708
-1,682
-10% -$15.6K ﹤0.01% 2244
2023
Q4 		$184K Sell
16,390
-2,247
-12% -$22.6K ﹤0.01% 2183
2023
Q3 		$161K Buy
18,637
+1,764
+10% +$17K ﹤0.01% 2200
2023
Q2 		$175K Sell
16,873
-570
-3% -$6.29K ﹤0.01% 2201
2023
Q1 		$189K Sell
17,443
-1,112
-6% -$11.8K ﹤0.01% 2193
2022
Q4 		$208K Buy
18,555
+829
+5% +$8.71K ﹤0.01% 2184
2022
Q3 		$180K Buy
17,726
+52
+0.3% +$487 ﹤0.01% 2224
2022
Q2 		$160K Buy
17,674
+7,149
+68% +$65.9K ﹤0.01% 2332
2022
Q1 		$101K Buy
+10,525
New +$103K ﹤0.01% 2425
2021
Q4 		– Sell
-24,799
Closed -$184K – 2628
2021
Q3 		$184K Buy
24,799
+9,949
+67% +$111K ﹤0.01% 2445
2021
Q2 		$216K Buy
14,850
+740
+5% +$13.9K ﹤0.01% 2454
2021
Q1 		$288K Sell
14,110
-9,666
-41% -$184K ﹤0.01% 2288
2020
Q4 		$422K Buy
23,776
+12,222
+106% +$219K ﹤0.01% 2153
2020
Q3 		$171K Sell
11,554
-572
-5% -$10.7K ﹤0.01% 2226
2020
Q2 		$255K Buy
12,126
+3,486
+40% +$89.5K ﹤0.01% 2126
2020
Q1 		$200K Buy
8,640
+373
+5% +$9.34K ﹤0.01% 2062
2019
Q4 		$214K Buy
+8,267
New +$161K ﹤0.01% 2124
2019
Q1 		– Sell
-7,907
Closed -$202K – 2242
2018
Q4 		$202K Sell
7,907
-6,725
-46% -$182K ﹤0.01% 2131
2018
Q3 		$478K Buy
+14,632
New +$399K ﹤0.01% 1968
2018
Q2 		– Sell
-9,674
Closed -$235K – 2306
2018
Q1 		$235K Buy
9,674
+868
+10% +$23.8K ﹤0.01% 2070
2017
Q4 		$246K Buy
8,806
+234
+3% +$6.92K ﹤0.01% 2092
2017
Q3 		$294K Sell
8,572
-5,757
-40% -$188K ﹤0.01% 2029
2017
Q2 		$571K Buy
14,329
+2,931
+26% +$113K ﹤0.01% 1928
2017
Q1 		$420K Buy
+11,398
New +$364K ﹤0.01% 1946

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Principal Financial Group's TBPH Position: Q2 2026 in Review

Principal Financial Group increased its Theravance Biopharma (TBPH) stake by 8.7% in Q2 2026, buying an estimated $75K and bringing the position to 56,792 shares worth $965K. The position accounts for ﹤0.01% of the portfolio, ranked #1944.

Principal Financial Group first reported a position in TBPH in Q1 2017 and has held it in 26 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Principal Financial Group held 56,792 shares of Theravance Biopharma worth $965K as of Q2 2026.
  • Principal Financial Group bought 4,528 Theravance Biopharma shares in Q2 2026, an estimated $75K.
  • Theravance Biopharma made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1944 holding.
  • Principal Financial Group first reported a position in Theravance Biopharma in Q1 2017 and has held it in 26 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.